drugset / Trial / NCT05397171
A First-in-human Study to Evaluate the Safety and Tolerability of AZD8853 in Participants With Selected Advanced/Metastatic Solid Tumours
Non-randomizedSequentialOpen-labelTreatment
Summary
A Phase I/IIa First-in-human, Open-label Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of AZD8853 in Participants with Selected Advanced/Metastatic Solid Tumours.
Timeline
- Start
- 2022-06-07
- Primary completion
- 2023-06-06
- Completion
- 2023-06-06
Outcome
Outcome not reported
Stopped: “This study was terminated early as per protocol Section 4.4, based on overall risk-benefit profile observed to date. No safety concerns reported. Only Substudy 1 Part A was started; Parts B \& C were not started. Entire Master Protocol was terminated.”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | AZD8853 | Unknown | — | — |
| Subject | Zirconium-89 crefmirlimab berdoxam | Diagnostic / imaging agent | — | — |